The global prental diagnostic market is anticipated to grow at a considerable CAGR of 12.9% during the forecast period. Prenatal diagnostic is a set of critical procedures, which performs during pregnancy through screening tests to detect the risk of possible health issues in the baby. Prenatal diagnostic tests are performed through invasive screening and non-invasive screening. To overcome, the challenges of chromosomal abnormalities, congenital heart conditions, and other issues, prenatal diagnostic test is conducted. Moreover, the prenatal diagnostic is widely used to detect the health problems before and after the birth of the baby, such as birth defects, in which the shape or function of one or more parts of the body changes after birth, genetic and chromosomal conditions which are caused by changes in genes and chromosomes, and down syndrome. According to USCF Health Down syndrome is a genetic condition caused by extra genes from 21st chromosomes, that results in upward slant of the eyes, flattered bridge of the nose, and decreased muscle tone, the incidence of Down syndrome in the US is around 1 in 1,000 births. Prenatal diagnostic enables the parents to prepare socially, medically, financially, and psychologically for having the probability of genetic disorder in the baby. 

The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, Chinese gene company BGI Group in collaboration with the Chinese military, People’s Liberation Army (PLA), took prenatal tests and sold the data across the globe. With this collaboration, China propels the growth in the pharmaceuticals industry and detects abnormalities such as Down syndrome in the fetus of the mother during pregnancy.

Further, when the woman is in maternal age, an age of women at the time of delivery, advancing maternal age can result in several health complications, such as decreased fertility, high blood pressure, and an increased risk of miscarriage. The advancing maternal age can lead to an increase in genetic disorders in babies. Owing to increasing genetic abnormalities resulting from improper chromosomal division leads to down syndrome, hence results in growing demand for developing an effective and accurate diagnostic procedure for early monitoring of disorders in pregnant mothers. Thus, increasing maternal age, along with the increasing incidence of chromosomal abnormalities among pregnant women, is lucrative to drive the demand for the prenatal diagnostic market in the coming years. According to the Centers for Disease Control and Prevention, Down syndrome remains the most common chromosomal situation diagnosed in the US. Each year, about 6,000 babies born in the US suffered from down syndrome. It shows that this occurs in about 1 in every 700 babies.

The high cost of the prenatal diagnostic test is not affordable in many developing countries and is likely to limit their adoption. According to milaap.org the cost of a prenatal diagnostic test in India is ranges from $4.81 to $5.35, this hinders the growth of the market in emerging countries. Additionally, lower per capita income, lack of awareness among the general population,and lack of technical skills and expertise heathcare personnel in the developing countries limits the growth of global prenatal diagnostic market.  

Impact of COVID-19 Pandemic on Global Prenatal Diagnostic Market

The Prenatal Diagnostic market has registered a decline in growth due to the COVID-19 pandemic. The sudden outbreak globally limited the market growth. Most of the industries across the globe have been negatively affected by the COVID-19 pandemic over the last year. Restrictions, and lockdowns enforced by government authorities, results in a restriction on mobility, the number of patient visits in the hospitals and clinics has been reduced. Moreover, the pressure on the hospitals to provide services to COVID-19 patients is another factor inhibiting the hospitals and specialty clinics from assisting with prenatal screening. As a result, most of prenatal diagnostics have to be put on hold, which leads to less treatment demand. Apart from these, the mobility restrictions on labor, essential products affect the supply chain that resulted in the dealy in the product supply to end-user.   

Segmental Outlook 

The prenatal diagnostic market is segmented based on the method, test type and end-user. Based on the method, the market is augmented into blood, urine, ultrasound, amniocentesis and others (percutaneous umbilical blood sampling). Based on test type the market is bifurcated into invasive, and non-invasive. Based on end-user the market is divided into hospitals, specialty clinics, and diagnostic centers. Among these, the diagnostic centers segment dominated other end-user segments in the share of revenue in the global market. Increasing cases of miscarriages, and chromosomal abnormalities in the mother increases the demand for a prenatal diagnostic test in specialtiy clinics in coming future. Moreover, increasing demand for the non-invasive test, technological innovations in the prenatal diagnostic market,rising number of diagnostic centers, and involvement of trained and experienced specialists across the globe driving this segment’s revenue growth.

Global Prenatal Diagnostic Market Share by Method, 2020 (%)

The Ultrasound Segment Holds the Major Share in the Global Prenatal Diagnostic Market.

The ultrasound segment is expected to register the fastest revenue growth rate in the coming years. The factors that are boosting the revenue growth include rising preference for ultrasound prenatal testing procedures owing to its wider advantages such as non-invasiveness testing, increased safety, and improved diagnosis. Further, increased safety advances in ultrasound technology and rapid adoption of 3D and 4D ultrasound imaging solutions is further driving the segment growth. For instance, in January 2021, Royal Philips announced a partnership with Merck. With this partnership both the companies developed clinical-grade digital solutions for highly personalized fertility treatment. The partnership of the company brings expertise in maternal and fetal monitoring, pregnancy + and baby+consumer engagement apps, by using the leading ultrasound solutions and HeatlhSuite Cloud/AI platform. With the leveraging of digital health technologies, advanced informatics, and AI-enabled ultrasound diagnostics, the company will provide information to patients and clinics about the choice and timing of fertility treatment to minimize the occurrence of misconception.

Regional Outlooks

The global prental diagnostic market is further segmented based on geography including North America (the US, and Canada), Europe (UK,Italy, Spain, Germany, France, and rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and rest of Asia-Pacific), and the Rest of the World (the Middle East &Africa, and Latin America). North-America region holds the major share in the market followed by Asia-Pacifc , and then Europe. The fators that affecting the growth in the region includes, coalitions between companies and hospitals and increasing penetration of the prenatal testing procesures. 

Global Prenatal Diagnostic Market Growth, by Region 2021-2027

The North-America Region Holds the Major Share in the Global Prenatal Diagnostic Market.

The North-America is expected to hold a lucrative share in prenatal diagnostic market during the forecast period. Increasing incidence of chromosomal abnormalities , higher maternal mortality rate will substantially increase the adoption and demand of prenatal diagnostic tests in the region. Moreover, high rates of diagnosis centers, wider application and adoption of advanced technologies among the people , and coupled with rising awareness among the people are also contributing to the growth of the market in North-America. Additionally, increase in the rate of hig risk pregnancies and rising average age for the child bearing , results in the development of chromosomal disorders, and hence the market is anticipated to propelled in the coming years. For instance, in august, 2021, BioReferences laboraties  has acquired US Ariosa Roche’s prenatal test business. Both the company is offering non-invasive prenatal screening test called harmony prenatal. With this acquisition US arisona’s harmony will round out the company’s prenatal screening portfolio.  

Market Players Outlook

The major companies serving the global prenatal diagnostic market include Abbott, Eurofines NTD Inc., Illumina’s Inc, Myriad  Genetics Inc., Quest Diangostics Inc., Hologic Inc., Natera Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2019, Invitae Corp. has acquired Single Bio Inc. With this acquisition, the technology used by the companies help to make the routine non-invasive prenatal screening widely available.  The company put the efforts to deliver cost reduction treatment, thst allow more patients to benefit form essential health information.      

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global prenatal diagnostic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.